ESPE Abstracts (2021) 94 P2-358

ESPE2021 ePoster Category 2 Pituitary, neuroendocrinology and puberty (48 abstracts)

Pubertal induction in girls with hypogonadism: preliminary prospective data of efficacy in patients with/without initial overnight estrogen replacement

Giulia Rodari 1,2 , Silvia Federici 3,4 , Luca Persani 3,4 , Maura Arosio 1,2 , Marco Bonomi 3,4 & Claudia Giavoli 1,2

1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Milan, Italy; 2University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 3University of Milan Department of Medical Biotechnology and Translational Medicine, Milan, Italy; 4IRCCS Istituto Auxologico Italiano, Department of Endocrine and Metabolic Diseases and Lab. of Endocrine and Metabolic Research, Milan, Italy

Background: Pubertal induction in girls with hypogonadism through estrogen replacement therapy (ERT) aims at the development of secondary sexual characteristics, cognitive functions, uterine growth and maturation, bone mass accrual and linear growth. To date, the best induction regimen, capable of assuring both physiological gradual progression through Tanner stages and effective uterine development, is still to be established.

Patients and Methods: we prospectively followed 19 hypogonadal girls (16 with hypogonadotropic hypogonadism and 3 with premature ovarian insufficiency) pre-pubertal (Tanner stage B1) at baseline (mean age: 16.9±2.8 years, range: 11.7-24.8 years), for at least 12 months (range 1.0-4.2 years) after ERT start (transdermal 17βoestradiol patches). Eleven out of 19 patients started with overnight ERT for six months (0.07-0.1 mcg/kg/day). In all patients, ERT was gradually increased every six months. Progesterone replacement was started in 10 girls at Tanner stage 5 or bleeding occurrence. Auxological, biochemical (17βoestradiol), pelvic ultrasound and bone age assessment data were collected every 12 months from ERT start.

Results: mean tempo at Tanner stage B3 was 1.2±0.4 years, being negatively correlated with ERT dose/kg at start (P=0.01). Mean tempo at Tanner stage B4 was 2.0±0.5 years, being higher in patients with initial overnight ERT (P=0.02). Mean tempo at Tanner stage B5 or bleeding occurrence was 2.4±0.7 years, being positively correlated with uterine maturation (uterine length > 65 mm, P=0.02). Mean adult height (AH) was 171.3±6.1 cm (1.24±0.94 SDS WHO), not statistically different from mid-parental height (MPH-AH -0.6±1.4 SDS WHO, P=0.2). Uterine maturation was achieved by 71% patient at the end of induction, with final uterine length positively correlated with ERT dose/kg at progesterone introduction (P=0.02). No difference was found in uterine length between patients who underwent to initial overnight ERT and others.

Conclusions: our data indicate that (i) initial overnight ERT, resembling the nocturnal activation of hypothalamic-pituitary-gonadal axis and increasing mean tempo at Tanner stage B4, assures a gradual pubertal progression along with an adequate uterine maturation; (ii) delaying Tanner stage 5 achievement and bleeding occurrence seems to be beneficial in terms of uterine maturation. Further multicentric data are needed to confirm these evidences and the possible role of initial overnight ERT replacement.

Volume 94

59th Annual ESPE (ESPE 2021 Online)

22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.